| Ticker Symbol: | TPTX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 11085 North Torrey Pines Road La Jolla CA 92037 858 623-5665 |
| CEO/President: | Neil M. Kurtz M.D. |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Axonyx, Inc. is engaged in the business of acquiring and developing novel post-discovery central nervous system drug candidates, primarily in areas of memory and cognition. The company acquires patent rights to central nervous system pharmaceutical compounds with potential market impact and advance the compounds through clinical development towards regulatory approval. The company has acquired worldwide exclusive patent rights to three main classes of therapeutic compounds designed for the treatment of Alzheimer\'s Disease, Mild Cognitive Impairment, and related diseases. |
| Shares Outstanding: | 15,750 (000) | Market Value: | 2,530 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 19.61% | Number of Inst.Shareholders: | 43.50% |
| Last Quarter Sales: | 1.22 ($Mil.) | Last Quarter Net Income: | -5.39 ($Mil.) |
| Last Quarter EPS: | -0.34 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -1.58 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |